Interferon lambda as a potential treatment for COVID-19

References

• Clarke DL, Clifford RL, Jindarat S, et al. TNFα and IFNγ synergistically enhance transcriptional activation of CXCL10 in human airway smooth muscle cells via STAT-1, NF-κB, and the transcriptional coactivator CREB-binding protein. J Biol Chem. 2010;285(38):29101–29110. DOI:10.1074/jbc.M109.099952
   PubMed Web of Science ®Google Scholar
• Guo M, Li F, Ji J, et al. Inhibition of miR-93 promotes interferon effector signaling to suppress influenza a infection by upregulating JAK1. Int Immunopharmacol. 2020;86:106754.
   PubMed Web of Science ®Google Scholar
• Znaidia M, Demeret C, van der Werf S, et al. Characterization of SARS-CoV-2 evasion: interferon pathway and therapeutic options. Viruses. 2022;14(6):1247.
   PubMed Web of Science ®Google Scholar
• Aschman T, Schaffer S, Biniaris Georgallis SI, et al. Interferon lambda regulates cellular and humoral immunity in pristane-induced lupus. Int J Mol Sci. 2021;22(21):11747. DOI:10.3390/ijms222111747
   PubMed Web of Science ®Google Scholar
• Lasfar A, Zloza A, Silk AW, et al. Interferon lambda: toward a dual role in cancer. J Interferon Cytokine Res. 2019;39(1):22–29.
   PubMed Web of Science ®Google Scholar
• Peterson ST, Kennedy EA, Brigleb PH, et al. Disruption of Type III Interferon (IFN) Genes. J Virol. 2019;93(22):2212–2223.
   Web of Science ®Google Scholar
• Gimeno Brias S, Marsden M, Forbester J, et al. Interferon lambda is required for interferon gamma-expressing NK cell responses but does not afford antiviral protection during acute and persistent murine cytomegalovirus infection. PLoS ONE. 2018;13(5):e0197596. DOI:10.1371/journal.pone.0197596
   PubMed Web of Science ®Google Scholar
• Mozhgani SH, Jahantigh HR, Rafatpanah H, et al. Interferon Lambda Family along with HTLV-1 Proviral Load, Tax, and HBZ Implicated in the Pathogenesis of Myelopathy/Tropical Spastic Paraparesis. Neurodegener Dis. 2018;18(2–3):150–155. DOI:10.1159/000490058
   PubMed Web of Science ®Google Scholar
• Hemann EA, Gale M, Savan R. Interferon lambda genetics and biology in regulation of viral control. Front Immunol. 2017;8:1707. DOI:10.3389/fimmu.2017.01707
   PubMed Web of Science ®Google Scholar
• de Weerd NA, Nguyen T, Weerd NA. The interferons and their receptors—distribution and regulation. Immunol Cell Biol. 2012;90(5):483–491.
   PubMed Web of Science ®Google Scholar
• Bozorgmehr N, Mashhouri S, Perez Rosero E, et al. Galectin-9, a player in cytokine release syndrome and a surrogate diagnostic biomarker in SARS-CoV-2 Infection. MBio. 2021;12(3).
   PubMed Web of Science ®Google Scholar
• Sa Ribero M, Jouvenet N, Dreux M, et al. Interplay between SARS-CoV-2 and the type I interferon response. PLOS Pathog. 2020;16(7):e1008737. DOI:10.1371/journal.ppat.1008737
   PubMed Web of Science ®Google Scholar
• Dechamps M, De Poortere J, Octave M, et al. Dexamethasone modulates the cytokine response but Not COVID-19-Induced Coagulopathy in Critically Ill. Int J Mol Sci. 2023;24(8):7278. DOI:10.3390/ijms24087278
   PubMed Web of Science ®Google Scholar
• RM S, Altyar A E, Essam Abou Warda A, et al. Pentoxifylline effects on hospitalized COVID-19 patients with cytokine storm syndrome: a randomized clinical trial. Pharmaceuticals (Basel). 2023;16(4):631. DOI:10.3390/ph16040631
   PubMedGoogle Scholar
• Elbadawy HM, Khattab A, El-Agamy DS, et al. IL-6 at the center of cytokine storm: circulating inflammation mediators as biomarkers in hospitalized COVID-19 patients. J Clin Lab Anal. 2023;48:e24881.
   Google Scholar
• McCarthy MW. Treatment of severe COVID-19: an evolving paradigm. Expert Opin Pharmacother. 2022;23(17):1–5.
   PubMed Web of Science ®Google Scholar
• Oleinik LA, Madonov PG, Pykhtina MB. Potential of Interferon Lambda as an Inhibitor of SARS-CoV-2. Mol Biol (Mosk). 2023;57(2):307–315.
   PubMed Web of Science ®Google Scholar
• Sette A, Crotty S. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. Immunol Rev. 2022;310(1):27–46. DOI:10.1111/imr.13089
   PubMed Web of Science ®Google Scholar
• Kuchroo M, Huang J, Wong P, et al. Multiscale PHATE identifies multimodal signatures of COVID-19. Nat Biotechnol. 2022;40(5):681–691. DOI:10.1038/s41587-021-01186-x
   PubMed Web of Science ®Google Scholar
• Wang N, Zhan Y, Zhu L, et al. Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 Patients. Cell Host Microbe. 2020;28(3):455–64.e2. DOI:10.1016/j.chom.2020.07.005
   PubMed Web of Science ®Google Scholar
• Santer DM, Li D, Ghosheh Y, et al. Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity. Nat Commun. 2022;13(1):6992. DOI:10.1038/s41467-022-34709-4
   PubMed Web of Science ®Google Scholar
• Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22(5):315–329. DOI:10.2165/00063030-200822050-00004
   PubMed Web of Science ®Google Scholar
• Klein ME, Mauch S, Rieckmann M, et al. Phosphatidylserine (PS) and phosphatidylglycerol (PG) nanodispersions as potential anti-inflammatory therapeutics: comparison of in vitro activity and impact of pegylation. Nanomedicine. 2020;23:102096.
   PubMed Web of Science ®Google Scholar
• Ramírez MLÁ, Bindini E, Moretti P, et al. Impact of PEGylation on the degradation and pore organization in mesoporous silica nanoparticles: a study of the inner mesoporous structure in physiologically relevant ionic conditions. Colloids Surf B Biointerfaces. 2022;219:112797.
   PubMed Web of Science ®Google Scholar
• Yu J, Xu D, Yu B. Efficacy and safety of peginterferon. Contrast Media Mol Imaging. 2022;2022:7623832.
   PubMed Web of Science ®Google Scholar
• Chan HLY, Ahn SH, Chang TT, et al. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: a randomized phase 2b study (LIRA-B). J Hepatol. 2016;64(5):1011–1019. DOI:10.1016/j.jhep.2015.12.018
   PubMed Web of Science ®Google Scholar
• Utay NS, Douek DC. Interferons and HIV infection: the good, the bad, and the ugly. Pathog Immun. 2016;1(1):107–116.
   PubMedGoogle Scholar
• Dinnon KH, Leist SR, Schäfer A, et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020;586(7830):560–566. DOI:10.1038/s41586-020-2708-8
   PubMed Web of Science ®Google Scholar
• Andreakos E, Tsiodras S. COVID-19: lambda interferon against viral load and hyperinflammation. EMBO Mol Med. 2020;12(6):e12465.
   PubMed Web of Science ®Google Scholar
• Kotenko SV, Gallagher G, VV B, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4(1):69–77. DOI:10.1038/ni875
   PubMed Web of Science ®Google Scholar
• Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4(1):63–68. DOI:10.1038/ni873
   PubMed Web of Science ®Google Scholar
• Ye L, Schnepf D, Staeheli P. Interferon-λ orchestrates innate and adaptive mucosal immune responses. Nat Rev Immunol. 2019;19(10):614–625.
   PubMed Web of Science ®Google Scholar
• Davidson S, McCabe TM, Crotta S, et al. IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment. EMBO Mol Med. 2016;8(9):1099–1112. DOI:10.15252/emmm.201606413
   PubMed Web of Science ®Google Scholar
• Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of Type I and Type III Interferons. Immunity. 2019;50(4):907–923. DOI:10.1016/j.immuni.2019.03.025
   PubMed Web of Science ®Google Scholar
• Klinkhammer J, Schnepf D, Ye L, et al. IFN-λ prevents influenza virus spread from the upper airways to the lungs and limits virus transmission. Elife. 2018;7. DOI:10.7554/eLife.33354
   PubMed Web of Science ®Google Scholar
• Muir AJ, Arora S, Everson G, et al. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol. 2014;61(6):1238–1246. DOI:10.1016/j.jhep.2014.07.022
   PubMed Web of Science ®Google Scholar
• Nelson M, Rubio R, Lazzarin A, et al. Safety and efficacy of pegylated interferon lambda, ribavirin, and daclatasvir in HCV and HIV-Coinfected Patients. J Interferon Cytokine Res. 2017;37(3):103–111. DOI:10.1089/jir.2016.0082
   PubMed Web of Science ®Google Scholar
• Dijkman R, Verma AK, Selvaraj M, et al. Effective interferon lambda treatment regimen to control lethal MERS-CoV infection in mice. J Virol. 2022;96(11):e0036422. DOI:10.1128/jvi.00364-22
   PubMed Web of Science ®Google Scholar
• Prokunina-Olsson L, Alphonse N, Dickenson RE, et al. COVID-19 and emerging viral infections: the case for interferon lambda. J Exp Med. 2020;217(5):791–798.
   Web of Science ®Google Scholar
• Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respir Med. 2021;9(5):498–510. DOI:10.1016/S2213-2600(20)30566-X
   PubMed Web of Science ®Google Scholar
• Reis G, Moreira Silva EAS, Medeiros Silva DC, et al. Early treatment with pegylated interferon lambda for Covid-19. N Engl J Med. 2023;388(6):518–528. DOI:10.1056/NEJMoa2209760
   PubMed Web of Science ®Google Scholar
• McCrindle BW, Harahsheh AS, Handoko R, et al. SARS-CoV-2 variants and multisystem inflammatory syndrome in children. N Engl J Med. 2023;388(17):1624–1626. DOI:10.1056/NEJMc2215074
   PubMed Web of Science ®Google Scholar
• Ridgway JP, Tideman S, Wright B, et al. Decreased risk of coronavirus disease 2019-related hospitalization associated with the omicron variant of severe acute respiratory syndrome coronavirus 2. Open Forum Infect Dis. 2022;9(7):ofac288.
   PubMed Web of Science ®Google Scholar
• McCarthy MW, Naggie S, Boulware DR, et al. Effect of fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2023;329(4):296. DOI:10.1001/jama.2022.24100
   PubMed Web of Science ®Google Scholar
• Naggie S, Boulware DR, Lindsell CJ, et al. Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;328(16):1595–1603. DOI:10.1001/jama.2022.18590
   PubMed Web of Science ®Google Scholar
• Naggie S, Boulware DR, Lindsell CJ, et al. Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with COVID-19: a randomized clinical trial. JAMA. 2023;329(11):888–897. DOI:10.1001/jama.2023.1650
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021;384(8):693–704.
   PubMed Web of Science ®Google Scholar
• McCarthy MW. Outpatient treatment options to address the SARS-CoV-2 variant Omicron. Expert Rev Anti Infect Ther. 2022;20(8):1–5.
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–1408. DOI:10.1056/NEJMoa2118542
   PubMed Web of Science ®Google Scholar
• Ganatra S, Dani SS, Ahmad J, et al. Oral nirmatrelvir and ritonavir in non-hospitalized vaccinated patients with covid-19. Clin Infect Dis. 2022;76:563–572 .
   Web of Science ®Google Scholar
• Wang Y, Chen X, Xiao W, et al. Rapid COVID-19 rebound in a severe COVID-19 patient during 20-day course of Paxlovid. J Infect. 2022;85(5):e134–6.
   PubMed Web of Science ®Google Scholar
• Coulson JM, Adams A, Gray LA, et al. COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy. J Infect. 2022;85(4):436–480. DOI:10.1016/j.jinf.2022.06.011
   PubMed Web of Science ®Google Scholar
• Gottlieb RL, Juneja K, Hill JA. Outpatient remdesivir to prevent progression to severe covid-19. Reply N Engl J Med. 2022;386(11):1094.
   PubMed Web of Science ®Google Scholar
• Candel FJ, Salavert M, Lorite Mingot D, et al. Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated with monoclonal antibodies. Rev Esp Quimioter. 2023. DOI:10.37201/req/023.2023
   Web of Science ®Google Scholar
• Ambrose N, Amin A, Anderson B, et al. Neutralizing monoclonal antibody use and COVID-19 Infection Outcomes. JAMA Netw Open. 2023;6(4):e239694. DOI:10.1001/jamanetworkopen.2023.9694
   PubMed Web of Science ®Google Scholar
• Luo J, Li A, Liu C, et al. The effect of bebtelovimab on clinical outcomes in patients with COVID-19: a meta-analysis. J Infect. 2023. DOI:10.1016/j.jinf.2023.04.010
   Google Scholar
• Molina KC, Kennerley V, Beaty LE, et al. Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron Variants including BA.4/BA.5. Int J Infect Dis. 2023;132:34–39.
   PubMed Web of Science ®Google Scholar
• Sodeifian F, Nikfarjam M, Kian N, et al. The role of type I interferon in the treatment of COVID-19. J Med Virol. 2022;94(1):63–81. DOI:10.1002/jmv.27317
   PubMed Web of Science ®Google Scholar
• Sohn SY, Hearing J, Mugavero J, et al. Interferon- lambda intranasal protection and differential sex pathology in a murine model of SARS-CoV-2 Infection. MBio. 2021;12(6):e0275621. DOI:10.1128/mBio.02756-21
   PubMed Web of Science ®Google Scholar
• Basu S. Computational characterization of inhaled droplet transport to the nasopharynx. Sci Rep. 2021;11(1):6652.
   PubMed Web of Science ®Google Scholar
• Collins FS, Stoffels P. Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): an unprecedented partnership for unprecedented times. JAMA. 2020;323(24):2455–2457.
   PubMed Web of Science ®Google Scholar
• McCarthy MW. Novel Strategies for the Treatment of COVID-19. Drugs in R&D. 2022;22(4):257–262.
   PubMed Web of Science ®Google Scholar
• LaVange L, Adam SJ, Currier JS, et al. Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): designing Master Protocols for Evaluation of Candidate COVID-19 Therapeutics. Ann Intern Med. 2021;174(9):1293–1300. DOI:10.7326/M21-1269
   PubMed Web of Science ®Google Scholar
• Ko ER, Anstrom KJ, Panettieri RA, et al. Abatacept for Treatment of Adults Hospitalized with Moderate or Severe Covid-19. medRxiv. 2022.
   Google Scholar
• O’Halloran J, Kedar E, Anstrom KJ, et al. Infliximab for treatment of adults hospitalized with moderate or severe covid-19. medRxiv 2022.
   Google Scholar
• Group AC-TIaVA-SNaggie S, Inhaled fluticasone for outpatient Treatment of Covid-19: a decentralized, placebo-controlled, randomized. Platform Clinical Trial medRxiv. 2022;55:1118–1127 .
   Google Scholar
• Jagannathan P, Andrews JR, Bonilla H, et al. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nat Commun. 2021;12(1):1967. DOI:10.1038/s41467-021-22177-1
   PubMed Web of Science ®Google Scholar